Home THERAPY AREAS Iron therapy in patients with HF: preclinical data 18 February 2022 Iron Deficiency Iron Deficiency Presented as part of Vifor Pharma's medical booth at the HFA 2021 Congress, held virtually on May 15–18, 2021. Iron deficiency in patients with chronic HF is associated with reduced exercise performance, impaired health-related quality of life (QoL), and an increased risk of mortality, independent of the presence of anemia. The importance of addressing iron deficiency in patients with HF is reflected in the European Society of Cardiology and American College of Cardiology Foundation/American Heart Association guidelines, which recognize iron deficiency as an important comorbidity in patients with HF, independent of the presence of anemia. Watch Prof. Peter van der Meer (University Medical Center Groningen, Groningen, The Netherlands) review the burden, outcomes, and pathophysiology of iron deficiency in HF and discuss the preclinical data that support the clinical efficacy of iron therapies in this common but often overlooked condition. THERE IS MORE HERE Specialist information is located in this area. In order to be able to see this, you must verify yourself as a healthcare professional. ?